AnaptysBio Inc Stock
AnaptysBio Inc Stock
There is no change in the price for AnaptysBio Inc today.
The stock is an absolute favorite of our community with 22 Buy predictions and no Sell predictions.
With a target price of 64 € there is a positive potential of 20.75% for AnaptysBio Inc compared to the current price of 53.0 €.
So far the community has only identified positive things for AnaptysBio Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of AnaptysBio Inc in the next few years
Pros
?
B****
?
S********** s********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of AnaptysBio Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AnaptysBio Inc | 0.000% | 13.938% | 27.475% | 236.601% | 19.767% | 147.596% | 218.196% |
| Immunic Inc. | 10.280% | 21.814% | 65.154% | 11.573% | 162.326% | -27.296% | -91.582% |
| Ocuphire Pharma Inc. | 3.230% | 14.188% | 42.347% | 358.379% | 148.811% | 29.607% | - |
| NanoViricides Inc. | -1.820% | 1.899% | 14.184% | -23.333% | -13.441% | -34.446% | -80.172% |
Comments
AnaptysBio (ANAB) had its price target raised by Stifel Nicolaus from $56.00 to $85.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio (ANAB) had its price target raised by Barclays PLC from $78.00 to $79.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio (ANAB) had its price target raised by HC Wainwright from $51.00 to $66.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
News
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally
On Dec. 23, AnaptysBio (NASDAQ:ANAB) Director J. Anthony Ware executed an open-market sale of 3,900 shares for a transaction value of $193,342.50, representing 28.82% of his direct holdings
What Investors Should Know About a $163K AnaptysBio Insider Sale
Paul F. Lizzul, the chief medical officer of AnaptysBio (NASDAQ:ANAB), reported the direct sale of 3,650 shares of the company for a total consideration of approximately $163,191.50 on Thursday, as